Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the role of pharmacy benefit companies in the prescription drug supply chain in a new Forbes
Bass Explains Opposition to Legislation, Risk of Drug Companies Lowering Rx Discounts On Wednesday, expert witnesses testifying before the U.S. House Committee on Energy & Commerce Subcommittee on Health highlighted the critical value pharmacy benefit companies provide for patients, employers, and
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
In case you missed it, Ike Brannon, health care economist and senior fellow at the Jack Kemp Foundation, published a new white paper, “Recently Proposed Federal and State Legislation To Constrain Pharmacy Benefit Managers Would Not Reduce Drug Costs,” in
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you missed it, the Coalition for Affordable Prescription Drugs (CAPD), an organization that represents a diverse
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. P&T COMMITTEES FOLLOW THE SCIENCE… Covering effective drugs for the broad
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed are generics or biosimilars. During last week’s hearing in the House Oversight Committee, Dr. Rena
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former White House domestic policy adviser,
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case you missed it, Senator Rand Paul (R-KY) discusses recent legislation advanced by the Senate’s HELP
©2024 PCMA. All Rights Reserved.
